Reports of autism cases per 1,000 children grew dramatically in the US from 1996 to 2007.
The rapid increase in the number of autism cases in such a short period of time suggests that environmental factors are responsible for or a significant contributing factor in these types of diseases. However, complexity arises due to interactions among multiple genes, the environment and epigenetic factors which do not change DNA but are heritable and influence gene expression. Chart source Wikipedia.
More than half of US children diagnosed with ASD are prescribed psychoactive drugs or anticonvulsants, with the most common drug classes being antidepressants, stimulants, and antipsychotics. Aside from antipsychotics, there is scant reliable research about the effectiveness or safety of drug treatments for adolescents and adults with ASD. A person with autism may respond atypically to medications, the medications can have adverse effects, and no known medication relieves autism's core symptoms of social and communication impairments.
So essentially, conventional management of Autism does not address the cause of the disease and only attempts to treat the symptoms.
Recently it is becoming clear that immune system disfunction plays an important role in autism.
Altered immunity in individuals with Autism
Immunological abnormalities involving cytokines, immunoglobulins, inflammation and cellular activation have been noted in individuals with autism.
Alterations in various immune cells including Natural Killer Cells and Macrophages have also been observed in individuals with autism. Upon stimulation, NK cells from individuals with autism showed diminished cytotoxic activity.
Macrophage migration inhibitory factor (MIF or MMIF)
A cytokine recently linked to autism is macrophage migration inhibitory factor (MIF). MIF is a pro-inflammatory immune regulator that is constitutively expressed in brain tissues, and has important influences on neural and endocrine systems. This macrophage migration inhibitory factor cytokine is produced by neuroendocrine and immune tissues. Macrophage migration inhibitory factor possesses glucocorticoid-antagonist properties within the immune system and participates in the regulation of several endocrine circuits.
Plasma levels of macrophage migration inhibitory factor (MIF) were higher in individuals with autism.
Individuals with autism with the highest levels of plasma MIF were found to have the most severe behavioral symptoms.
Macrophage migration inhibitory factor is of critical importance for the host response to microbial infections and in several autoimmune diseases.
Macrophage migration inhibitory factor expression is usually constitutive at low levels.
Decreased levels of total plasma IgG and IgM have been observed in a large group of individuals with autism.
The reduced levels correlated with behavior, such that individuals with autism with the most severe behavioral symptom scores had the lowest IgG and IgM levels.
Altered sensitivity to environmental toxicants - PBDEs, immunity and autism
A complex interplay between immunological and environmental factors may have a role in autism. Polybrominated diphenyl ethers (PBDEs) are environmental toxicants that impact neurodevelopment and immunity. Individuals with ASD have different immune sensitivity to the environmental toxicant
Second Generation High Dose GcMAF immunotherapy is administered to overcome the problem of immune system disfunction, including that of macrophage migration inhibitory factor (MIF), which plays an integral role in autism and leads to commonly observed symptoms.
Recommended dose - 0.25ml High Dose GcMAF, twice weekly by intramuscular or subcutaneous injection. *
Some improvements in symptoms should be observed within 2 months.
Minimum treatment course of 6 months should be expected, but each individual patient is different and additional courses may be required based on positive progress.
Patients may need longer term maintenance doses of GcMAF therapy to stay well and symptom free until their immune system is fully developed enough to cope with challenges.
* These dosage recommendations apply only to Saisei Mirai Second Generation GcMAF.
If you wish to purchase GcMAF therapy or make an enquiry, please contact us with details of your disease, current treatment and the quantities of Gc-MAF you require.
We are very pleased to announce we now have an Instagram account!
You can find us at @saiseimirai or simply click here to view our feed on the web . We promise to post news about Saisei Mirai and GcMAF every day, so that you are aware of all the news as well as the success of our patients.
Seminar, at Arbetets Museum, Norrkoping,Sweden, May 29
Thank you Sweden, for your kindness and warm welcome!
Dr.Toshio Inui and Dr Kentaro Kubo gave prsentation about clinical use of GcMAF (+ Oral Colostrum MAF), and Skin cell injection therapy in Norrkoping, Sweden on May 29, 2018.
2018 Integrative Medical Conference－ Vilnius, Lithuania.
Thank you very much for your participation at the Saisei Mirai 2018 Integrative Medical Conference in Lithuania, held on Saturday 26 May 2018.
We hope that you found the conference informative and worthwhile.
Your presence helped to make this event a great success and your enthusiasm and positive spirit helped make our time together both productive and fun.
We wish you all the best and hope that you continue to be with the the Saisei Mirai.
Saisei Mirai X-MAF Series activate Macrophage.
Saisei Mirai Colostrum MAF has been in development for more than 10 years.
→ Saisei Pharma
Dr. Shinichiro Akiyama held seminars for Doctors and Patients in Tifana, Mexico on Apr 09, 11, 2018.
Dr. Antonio Jimenez, Chief Medical Officer of Hope4Cancer Treatment Centers, presents "The Importance of Emotions in Cancer" at a conference in Beaumont, Texas (Jan 2018).
Dr. Antonio Jimenez presenting at the “Un Mundo Sin Cancer” (“A World Without Cancer”) conference in Barcelona, Spain (Jan 2018).
Dr. Antonio Jimenez being interviewed in the Fox News Morning Show at Beaumont, Texas (Jan 2018).
Dr.Toshio Inui gave a presentation 「QSS JAPAN TEAM Year End Seminar」 in Tokyo, Japan on Dec 23, 2017.
Dr. Toshio Inui gave presentation in Faculty of Medicine of Vilnius University in Lithuania on Nov 30, 2017. He introduced Saisei Mirai Clinic and therapy methods available at Saisei Mirai Clinic in Japan.
Dr. Toshio Inui gave presentation in Vilnius University Hospital Santaros Klinikos in Lithuania, on Nov 29, 2017. He introduced Saisei Mirai Clinic and therapy methods available at Saisei Mirai Clinic in Japan.
2017 Integrative Medical Therapies Conference - Osaka, Japan
Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
International Pharmacy Conference
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
New research papers published by Saisei Mirai in Anticancer Research available online.
New research papers published by Saisei Mirai in Anticancer Research available online.
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.
Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.
Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.